In the Claims:

Please amend the claims as follows:

Claim 1. (original) A compound of formula (1) or a pharmaceutically acceptable salt, solvate, acid isostere, or hydrolyzable ester thereof;



(1)

wherein

R^1 and R^2 are independently hydrogen, F, CF_3, C_{1-3}alkyl, or R^1 and R^2 may together with the carbon atom to which they are attached form a 3 to 6-membered cycloakyl ring;

R^4 and R^5 are independently hydrogen, C_{1-6}alkyl, perfluoroC_{1-6}alkyl, -OC_{1-3}alkyl, perfluoroOC_{1-6}alkyl, halogen, or cyano;

R^7 and R^8 are independently H, F, CF_3, or C_{1-3}alkyl, and the carbon to which R^7 and R^8 are bonded is attached to the benzene ring either meta or para to the depicted oxygen;

n is 1 or 2;

y is 1 or 2;

R^6 is phenyl or a 5- or 6-membered heteroaryl group, where the phenyl or heteroaryl group is optionally substituted with 1, 2, or 3 moieties selected from the group consisting of C_{1-6}alkyl, halogen, perfluoroC_{1-3}alkyl, OC_{1-3}alkyl, perfluoroOC_{1-3}alkyl, SC_{1-3}alkyl, SO_2C_{1-3}alkyl, SO_2C_{1-3}perfluoroalkyl, SOC_{1-3}perfluoroalkyl, SOC_{1-3}alkyl, perfluoroSC_{1-3}alkyl, CN, phenyl (optionally substituted with one or two groups selected from halogen, C_{1-3}alkyl, OC_{1-3}alkyl, acetyl, CN, and perfluoroC_{1-3}alkyl), and 5- or 6-membered heteroaryl (optionally substituted with one group selected from C_{1-3}alkyl, C_{3-6}cycloalkyl, perfluoroC_{1-3}alkyl, NHC_{1-3}alkyl, and N(C_{1-3}alkyl)$_2$); and

R^3 is a 5- or 6-membered heteroaryl group optionally substituted by 1 or 2 moieties selected from the group consisting of halogen, C_{1-6}alkyl, perfluoroC_{1-6}alkyl, OC_{1-3}alkyl, phenyl (optionally substituted with one or two moieties selected from C_{1-3}alkyl, halogen, OC_{1-3}alkyl, acetyl, CN, OperfluoroC_{1-3}alkyl, and perfluoroC_{1-3}alkyl), 5- or 6-membered heteroaryl (optionally substituted with one or two moieties selected from C_{1-3}alkyl, halogen, OC_{1-3}alkyl, acetyl, CN, and perfluoroC_{1-3}alkyl), hydroxyC_{1-3}alkyl, C_{3-7}cycloalkyl, cyanoC_{1-3}alkyl, acetyl, nitro, N(CH_3)$_2$, NHR^{21} (where R^{21} is C_{1-3}alkyl, -C(O)C_{1-3}alkyl, -C(O)OC_{1-3}alkyl, or SO_2CH_3), piperidin-4-yl (substituted at nitrogen with a moiety selected from C_{1-5}alkyl, benzyl, acetyl, C(O)OC_{1-5}alkyl, C(O)Obenzyl, C(O)NH_2, C(O)NHC_{1-3}alkyl, SO_2CH_3), 4-(4-fluorophenyl)piperazin-1-ylmethyl, morpholin-4-ylmethyl, tetrahydrofuran-3-yl, or two adjacent carbon atoms in the heteroaryl could be substituted to form a benzene ring thus forming a fused bicycle and wherein the resulting benzene ring is optionally substituted with one or two moieties selected from C_{1-3}alkyl, halogen, and perfluoroC_{1-3}alkyl.

Claim 2. (original) A compound of Claim 1 wherein R^1 and R^2 are independently hydrogen or C_{1-3}alkyl.

Claim 3. (currently amended) A compound according to Claim 1 ~~any preceding claim~~ wherein R^1 and R^2 are both hydrogen or both methyl.

Claim 4. (currently amended) A compound according Claim 2 ~~to any preceding claim~~ wherein R^4 and R^5 are independently hydrogen, C_{1-3}alkyl, perfluoroC_{1-3}alkyl, -OC_{1-3}alkyl, perfluoroOC_{1-3}alkyl, halogen, or cyano.

Claim 5. (currently amended) A compound according to Claim 4 ~~any preceding claim~~ wherein at least one of R^4 and R^5 are hydrogen

Claim 6. (currently amended) A compound according to Claim 5 ~~any preceding claim~~ wherein one of R^4 and R^5 is hydrogen and the other is not.

Claim 7. (original) A compound according to Claim 6 wherein the one of R^4 and R^5 that is not hydrogen is ortho to the depicted oxygen.

Claim 8. (currently amended) A compound according Claim 5 ~~to any preceding claim~~ wherein R^7 and R^8 are independently hydrogen or methyl.

Claim 9. (currently amended) A compound according to Claim 5 ~~any preceding claim wherein~~ R^7 and R^8 are both hydrogen or both methyl.

Claim 10. (currently amended) A compound according to Claim 9 ~~any preceding claim~~ wherein y is 1.

Claim 11. (currently amended) A compound according to Claim 10 ~~any preceding claim~~ wherein R^6 is phenyl optionally substituted with 1 or 2 moieties selected from the group consisting of F, Cl, CF_3, OCF_3, 5-membered nitrogen-containing heteroaryl (optionally substituted with one group selected from C_{1-3}alkyl, C_{3-6}cycloalkyl, perfluoroC_{1-3}alkyl, NHC_{1-3}alkyl, and N$(C_{1-3}alkyl)_2$).

Claim 12. (currently amended) A compound according to Claim 11 ~~any preceding claim~~ wherein R^3 is selected from the group consisting of pyrimidine, pyridine, pyridazine, pyrazine, 1,2,4-

oxadiazole, oxazole, and thiazole; and is optionally substituted by a moiety selected from the group consisting of halogen, C_{1-6}alkyl, perfluoroC_{1-6}alkyl, phenyl (optionally substituted with one or two moieties selected from C_{1-3}alkyl, halogen, OC_{1-3}alkyl, acetyl, CN, and perfluoroC_{1-3}alkyl), 5- or 6-membered heteroaryl (optionally substituted with one or two moieties selected from C_{1-3}alkyl, halogen, OC_{1-3}alkyl, acetyl, CN, and perfluoroC_{1-3}alkyl), hydroxyC_{1-3}alkyl, and C_{3-7}cycloalkyl, or R^3 may be substituted to form a fused bicycle selected from benzoxazole and benzothiazole.

Claim 13. (currently amended) A compound according to Claim 12 ~~any preceding claim~~ wherein R^3 is a pyrimidine or a pyridine; and is optionally substituted by a moiety selected from the group consisting of halogen, C_{1-6}alkyl, perfluoroC_{1-6}alkyl, phenyl (optionally substituted with one or two moieties selected from C_{1-3}alkyl, halogen, OC_{1-3}alkyl, acetyl, CN, and perfluoroC_{1-3}alkyl), 5- or 6-membered heteroaryl, hydroxyC_{1-3}alkyl, and C_{3-7}cycloalkyl.

Claim 14. (original) A compound according to Claim 1 selected from the group consisting of:

2-(4-{2-[[2,4-Bis(trifluoromethyl)benzyl](5-ethylpyrimidin-2-yl)amino]ethyl}phenoxy)-2-methylpropanoic acid;

2-[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethyl)benzyl]amino}ethyl)-2-methoxyphenoxy]-2-methylpropanoic acid;

2-[2-Cyano-4-(2-{(5-ethylpyrimidin-2-yl)[4-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{(5-Ethylpyrimidin-2-yl)[3-(trifluoromethoxy)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{(5-Ethylpyrimidin-2-yl)[4-fluoro-2-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-(4-{2-[(4-chlorobenzyl)(5-ethylpyrimidin-2-yl)amino]ethyl}phenoxy)-2-methylpropanoic acid;

2-[4-(2-{(5-ethylpyrimidin-2-yl)[3-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-(4-{2-[(5-Ethylpyrimidin-2-yl)(4-fluorobenzyl)amino]ethyl}phenoxy)-2-methylpropanoic acid;

[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]acetic acid;

2-[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(5-isopropyl-1,2,4-oxadiazol-3-yl)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}ethyl)phenoxy]acetic acid;

[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}ethyl)-2-propylphenoxy]acetic acid;

5-Ethyl-*N*-{2-[3-propyl-4-(2*H*-tetraazol-5-ylmethoxy)phenyl]ethyl}-*N*-[4-(trifluoromethoxy)benzyl]pyrimidin-2-amine;

2-[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethyl)benzyl]amino}-1,1-dimethylethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{(5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}-1,1-dimethylethyl)phenoxy]-2-methylpropanoic acid;

[4-(2-{(5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}-1,1-dimethylethyl)phenoxy]acetic acid;

5-ethyl-*N*-{2-methyl-2-[4-(2*H*-tetraazol-5-ylmethoxy)phenyl]propyl}-*N*-[4-(trifluoromethoxy)benzyl]pyrimidin-2-amine;

[2-Chloro-4-(2-{(5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}-1,1-dimethylethyl)phenoxy]acetic acid;

2-[2-Chloro-4-(2-{(5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}-1,1-dimethylethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}-1,1-dimethylethyl)-2-propylphenoxy]-2-methylpropanoic acid;

[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}-1,1-dimethylethyl)-2-propylphenoxy]acetic acid;

2-[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}ethyl)-2-methylphenoxy]-2-methylpropanoic acid;

2-[2-Chloro-4-(2-{(5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}ethyl)-2-(trifluoromethyl)phenoxy]-2-methylpropanoic acid;

[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}ethyl)-2-methylphenoxy]acetic acid;

[4-(2-{(5-Ethylpyrimidin-2-yl)[4-(trifluoromethyl)benzyl]amino}ethyl)-2-fluorophenoxy]acetic acid;

[2-Chloro-4-(2-{(5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}ethyl)phenoxy]acetic acid;

2-[4-(2-{(5-Ethylpyridin-2-yl)[4-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{(5-Ethylpyridin-2-yl)[4-(trifluoromethoxy)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{(5-Isopropylpyridin-2-yl)[4-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{(5-Isopropylpyridin-2-yl)[4-(trifluoromethoxy)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-Methyl-2-[4-(2-{[5-(2,2,2-trifluoroethyl)pyridin-2-yl][4-(trifluoromethoxy)benzyl]amino}ethyl)phenoxy]propanoic acid;

2-[4-(2-{[5-(Hydroxymethyl)pyridin-2-yl][4-(trifluoromethoxy)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(3-{(5-Isopropylpyridin-2-yl)[4-(trifluoromethoxy)benzyl]amino}propyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{[4-(2-Chlorophenyl)-1,3-thiazol-2-yl][4-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

2-[4-(2-{[4-(3,4-Difluorophenyl)-1,3-thiazol-2-yl][4-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid;

and pharmaceutically acceptable salts, solvates, acid isosteres, and hydrolyzable esters thereof.

Claim 15. (original) A compound according to Claim 1 selected from the group consisting of: 2-[4-(2-{(5-ethylpyrimidin-2-yl)[4-(trifluoromethoxy)benzyl]amino}-1,1-dimethylethyl)phenoxy]-2-methylpropanoic acid, 2-[4-(2-{[4-(2-Chlorophenyl)-1,3-thiazol-2-yl][4-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid, 2-[4-(2-{[4-(3,4-Difluorophenyl)-1,3-thiazol-2-yl][4-(trifluoromethyl)benzyl]amino}ethyl)phenoxy]-2-methylpropanoic acid, and pharmaceutically acceptable salts, solvates, acid isosteres, and hydrolyzable esters thereof.

Claim 16. (original) A compound of according to Claim 1 wherein R^1 and R^2 are both hydrogen or both methyl; at least one of R^4 and R^5 are hydrogen; R^7 and R^8 are both hydrogen or both methyl; y is 1; R^6 is phenyl optionally substituted with 1 or 2 moieties selected from the group consisting of F, Cl, CF_3, OCF_3, 5-membered nitrogen-containing heteroaryl (optionally substituted with one group selected from C_{1-3}alkyl, C_{3-6}cycloalkyl, perfluoroC_{1-3}alkyl, NHC_{1-3}alkyl, and $N(C_{1-3}alkyl)_2$); and R^3 is a thiazole, a pyrimidine, or a pyridine and is optionally substituted by a moiety selected from the group consisting of halogen, C_{1-6}alkyl, perfluoroC_{1-6}alkyl, phenyl (optionally substituted with one or two moieties selected from C_{1-3}alkyl, halogen, OC_{1-3}alkyl, acetyl, CN, and perfluoroC_{1-3}alkyl), 5- or 6-membered heteroaryl, hydroxyC_{1-3}alkyl, and C_{3-7}cycloalkyl.

Claim 17. (currently amended) A compound according to Claim 1 ~~any preceding claim~~ wherein the compound is a hPPAR agonist.

Claim 18. (original) A method for prevention or treatment of a disease or condition associated with one or more of human PPAR alpha, gamma, or delta ("hPPARs") comprising administration of a therapeutically effective amount of a compound of Claim 17.

Claim 19. (original) The method of Claim 18 wherein said disease or condition is selected from the group consisting of dyslipidemia including associated diabetic dyslipidemia and mixed dyslipidemia, syndrome X, heart failure, hypercholesteremia, cardiovascular disease including atherosclerosis, arteriosclerosis, and hypertriglyceridemia, type II diabetes mellitus, type I diabetes, insulin resistance, hyperlipidemia, inflammation, epithelial hyperproliferative diseases including eczema and psoriasis and conditions associated with the lung and gut and regulation of appetite and food intake in subjects suffering from disorders such as obesity, anorexia bulimia, and anorexia nervosa.

Claim 20. (original) The method of Claim 18 wherein said disease or condition is selected from the group consisting of diabetes and cardiovascular diseases and conditions including atherosclerosis, arteriosclerosis, hypertriglyceridemia, and mixed dyslipidemia.

Claim 21. (currently amended) A pharmaceutical composition comprising a compound according to Claim 1 ~~any preceding claim~~.

Claims 22 and 23 are deleted.

Express Mail Label No.
EV 332145954 US